1. Home
  2. AIV vs DSGN Comparison

AIV vs DSGN Comparison

Compare AIV & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apartment Investment and Management Company

AIV

Apartment Investment and Management Company

HOLD

Current Price

$4.24

Market Cap

837.1M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$14.20

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIV
DSGN
Founded
1975
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
837.1M
819.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
AIV
DSGN
Price
$4.24
$14.20
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$10.00
$15.25
AVG Volume (30 Days)
1.3M
493.9K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
87.41%
N/A
EPS Growth
616.00
N/A
EPS
3.87
N/A
Revenue
$138,486,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.94
$3.11
52 Week High
$8.87
$17.25

Technical Indicators

Market Signals
Indicator
AIV
DSGN
Relative Strength Index (RSI) 49.44 59.24
Support Level $4.03 $9.71
Resistance Level $4.28 $17.25
Average True Range (ATR) 0.06 1.16
MACD 0.02 0.01
Stochastic Oscillator 45.16 42.56

Price Performance

Historical Comparison
AIV
DSGN

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: